Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836533 | 0.86 | ELANE (0.49) | ESR1ESR2CYP3A4LMNAMAOB | |
| SCHEMBL287805 | 0.85 | CYP3A4 (0.63) | ESR1ESR2CYP3A4LMNAMAOB | |
| SCHEMBL27772040 | 0.81 | ESR1 (0.45) | ESR1ESR2CYP3A4MAOBNPC1 | |
| SCHEMBL9254323 | 0.80 | ESR1 (0.46) | ESR1ESR2CYP3A4LMNAMAOB | |
| SCHEMBL5487011 | 0.80 | ESR1 (0.54) | ESR1ESR2CYP3A4LMNAMAOB | |
| SCHEMBL4928156 | 0.79 | CYP3A4 (0.72) | ESR1ESR2CYP3A4LMNAMEN1 | |
| SCHEMBL4453562 | 0.79 | CES2 (0.53) | ESR1ESR2CYP3A4LMNANPC1 | |
| SCHEMBL11556061 | 0.79 | LMNA (0.72) | CYP3A4LMNAPPARGMEN1KMT2A | |
| SCHEMBL18697278 | 0.79 | ESR1 (0.53) | ESR1ESR2CYP3A4LMNANPC1 | |
| SCHEMBL17004183 | 0.79 | ESR1 (0.53) | ESR1ESR2CYP3A4LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174065-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | ZADEC APS (DK) | 2019-01-08 | — | — | US | disclosed |
| US-20160083411-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2016-03-24 | — | — | US | disclosed |
| US-9221860-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | ZADEC APS (DK) | 2015-12-29 | — | — | US | disclosed |
| EP-2625184-B1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2014-10-01 | — | — | EP | disclosed |
| US-20130310331-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2013-11-21 | — | — | US | disclosed |
| EP-2625184-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | Zadec ApS (DK) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012045363-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2012-04-12 | — | — | WO | disclosed |
| CN-101448824-A | 2,5-disubstituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-0206460-B1 | L-PHENYLALANINE DEHYDROGENASE AND USE THEREOF | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1993-08-11 | — | — | EP | disclosed |
| EP-0513872-A1 | L-phenylalanine dehydrogenase and use thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-11-19 | — | — | EP | disclosed |
| US-4849345-A | L-phenylalanine dehydrogenase and use thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-07-18 | — | — | US | disclosed |
| EP-0206460-A2 | L-phenylalanine dehydrogenase and use thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174065-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | PC, SLC5A1, SLC5A2 | ESR1 1014/4885ESR2 1067/4885CYP3A4 467/4885 |
| US-20160083411-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | PC, SLC5A1, SLC5A2 | ESR1 1014/4885ESR2 1067/4885CYP3A4 467/4885 |
| US-20130310331-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | PC, SLC5A1, SLC5A2 | ESR1 1014/4885ESR2 1067/4885CYP3A4 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.